Furthermore, in 2020, DMX-200 was selected for global studies to treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients (REMAP-CAP) and COVID-19-induced respiratory complications (CLARITY 2.0) due to the involvement of both AT1 and CCR2-mediated pathways in lung inflammation associated with infection with the SARS-CoV2 virus. This evidence concerns the gene AGTR1 and acute respiratory distress syndrome.